Biomarker treatment effects in two phase 3 trials of gantenerumab.
Bittner T, Tonietto M, Klein G, Belusov A, Illiano V, Voyle N, Delmar P, Scelsi MA, Gobbi S, Silvestri E, Barakovic M, Napolitano A, Galli C, Abaei M, Blennow K, Barkhof F.
Bittner T, et al. Among authors: klein g.
Alzheimers Dement. 2025 Jan 30:e14414. doi: 10.1002/alz.14414. Online ahead of print.
Alzheimers Dement. 2025.
PMID: 39887500